Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AdvaMed Launches National Search For New CEO As Ubl Plans Departure

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed CEO Steve Ubl is leaving the device trade association to take the helm of the Pharmaceutical Research and Manufacturers of America. Ubl has led AdvaMed for 10 years, raising the profile of the device industry among policymakers, fighting perception battles and, of course, opposing the device tax.

You may also be interested in...

Next AdvaMed Chief Is BIO Exec Scott Whitaker

Whitaker, appointed as the next CEO of AdvaMed, currently runs day-to-day operations at the Biotechnology Innovation Organization and has held high-level posts at HHS. Among his accomplishments, Whitaker led the legislative office at HHS when the first device user fee bill was passed in 2002.

PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise

Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.

Device Industry Amps Up Efforts To Repeal Device Tax In Lame Duck Session

Industry groups flew in more than 50 CEOs to visit Capitol Hill, launched an ad campaign and released an impact report last week as part of a stepped-up effort to get Congress to repeal the impending medical device tax before it goes into effect Jan. 1.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts